statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Significant Decrease in Short Interest

Ensysce Biosciences, Inc. (NASDAQ:ENSC - Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 56,500...

Q4 2023 Ensysce Biosciences Inc Earnings Call Transcript

Ensysce Biosciences reports Q4 EPS ($1.13) vs. ($18.30) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024...

Ensysce Biosciences receives positive Nasdaq listing determination

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the 'Company') (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

~ PF614-MPAR program receives FDA guidance ~SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical-stage company applying...

Ensysce Biosciences announces publication of clinical bioequivalence manuscript

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Publication Details Positive Results of Clinical Study PF614-102SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)(OTC PINK:ENSCW) ('Ensysce' or 'Company'), a...

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the 'Company'), a clinical-stage biotech company applying transformative chemistry to improve prescription...

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Volume	93,680.00
52-Wk High	$2.15
52-Wk Low	$0.3711

ENSC Ensysce Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals